Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of Neurology
Erschienen in: Journal of Neurology 1/2015

01.01.2015 | Review

Impulse control disorders in Parkinson’s disease: an overview from neurobiology to treatment

verfasst von: Emke Maréchal, Benjamin Denoiseux, Ellen Thys, David Crosiers, Barbara Pickut, Patrick Cras

Erschienen in: Journal of Neurology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Parkinson’s disease (PD) is the second most common neurodegenerative brain disorder and is characterized by motor symptoms such as tremor, bradykinesia, rigidity and postural instability. A majority of the patients also develop non-motor symptoms. Impulse control disorders (ICD) are behavioural changes that often fail to be detected in clinical practice. The prevalence of ICD in PD varies widely from 6.1 to 31.2 % and treatment with dopaminergic medication is considered to be the greatest risk factor. Management consists mainly of reducing dopaminergic medication. In our experience, ICD has a tremendous impact on the quality of life of the patients and their families and should therefore not be disregarded. Studies addressing the role of ICD in PD caregiver strain are imperative. We attempt to give a comprehensive overview of the literature on the complicated neurobiology of ICD and discuss risk factors, genetic susceptibility, screening modalities and management.
Literatur
1.
de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5(6):525–535PubMedCrossRef
2.
Voon V, Fox SH (2007) Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 64(8):1089–1096PubMedCrossRef
3.
Voon V et al (2006) Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 66(11):1750–1752PubMedCrossRef
4.
Burkhard PR et al. (2008) Impulse control disorders and Parkinson’s disease. Rev Med Suisse 4(156): 1145–1148, 1150.
5.
Ceravolo R et al (2009) Impulse control disorders in Parkinson’s disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord 15(Suppl 4):S111–S115PubMedCrossRef
6.
Pontone G et al (2006) Clinical features associated with impulse control disorders in Parkinson disease. Neurology 67(7):1258–1261PubMedCrossRef
7.
Bonfanti AB, Gatto EM (2010) Kleptomania, an unusual impulsive control disorder in Parkinson’s disease? Parkinsonism Relat Disord 16(5):358–359PubMedCrossRef
8.
Avanzi M et al (2008) The thrill of reckless driving in patients with Parkinson’s disease: an additional behavioural phenomenon in dopamine dysregulation syndrome? Parkinsonism Relat Disord 14(3):257–258PubMedCrossRef
9.
Bienfait KL et al (2010) Impulsive smoking in a patient with Parkinson’s disease treated with dopamine agonists. J Clin Neurosci 17(4):539–540PubMedCentralPubMedCrossRef
10.
Avanzi M et al (2006) Prevalence of pathological gambling in patients with Parkinson’s disease. Mov Disord 21(12):2068–2072PubMedCrossRef
11.
12.
Lee JY et al (2009) Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson’s disease. Mov Disord 24(12):1803–1810PubMedCrossRef
13.
Lee JY et al (2010) Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord 16(3):202–207PubMedCrossRef
14.
Weintraub D et al (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67(5):589–595PubMedCrossRef
15.
Voon V et al (2006) Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67(7):1254–1257PubMedCrossRef
16.
Singh A et al (2007) Risk factors for pathologic gambling and other compulsions among Parkinson’s disease patients taking dopamine agonists. J Clin Neurosci 14(12):1178–1181PubMedCrossRef
17.
Fan W et al (2009) Impulse control disorders in Parkinson’s disease in a Chinese population. Neurosci Lett 465(1):6–9PubMedCrossRef
18.
Weintraub D et al (2009) Validation of the questionnaire for impulsive-compulsive disorders in Parkinson’s disease. Mov Disord 24(10):1461–1467PubMedCentralPubMedCrossRef
19.
Shaffer HJ, Hall MN, Bilt JV (1999) Estimating the prevalence of disordered gambling behavior in the United States and Canada: a research synthesis. Am J Public Health 89(9):1369–1376PubMedCentralPubMedCrossRef
20.
Petry NM, Stinson FS, Grant BF (2005) Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 66(5):564–574PubMedCrossRef
21.
American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision (DSM-IV-TR). Amercian Psychiatric Association, Washington, DC
22.
Fiorillo CD, Tobler PN, Schultz W (2003) Discrete coding of reward probability and uncertainty by dopamine neurons. Science 299(5614):1898–1902PubMedCrossRef
23.
Lim SY et al (2009) Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson’s disease. J Clin Neurosci 16(9):1148–1152PubMedCrossRef
24.
Gescheidt T, Bares M (2011) Impulse control disorders in patients with Parkinson’s disease. Acta Neurol Belg 111(1):3–9PubMed
25.
Jimenez-Jimenez FJ et al (2002) Possible zoophilia associated with dopaminergic therapy in Parkinson disease. Ann Pharmacother 36(7–8):1178–1179PubMedCrossRef
26.
McElroy SL et al (1994) Compulsive buying: a report of 20 cases. J Clin Psychiatry 55(6):242–248PubMed
27.
Molina JA et al (2000) Pathologic gambling in Parkinson’s disease: a behavioral manifestation of pharmacologic treatment? Mov Disord 15(5):869–872PubMedCrossRef
28.
29.
Ondo WG, Lai D (2008) Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord 14(1):28–32PubMedCrossRef
30.
Giovannoni G et al (2000) Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68(4):423–428PubMedCentralPubMedCrossRef
31.
Wolters E, van der Werf YD, van den Heuvel OA (2008) Parkinson’s disease-related disorders in the impulsive-compulsive spectrum. J Neurol 255(Suppl 5):48–56PubMedCrossRef
32.
Storch A et al (2013) Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 80(9):800–809PubMedCrossRef
33.
Pezzella FR et al (2005) Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson’s disease. Mov Disord 20(1):77–81PubMedCrossRef
34.
Cilia R et al (2014) Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome. J Neurol Neurosurg Psychiatry 85(3):311–318
35.
Evans AH et al (2004) Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19(4):397–405PubMedCrossRef
36.
37.
Isaias IU et al (2008) The relationship between impulsivity and impulse control disorders in Parkinson’s disease. Mov Disord 23(3):411–415PubMedCrossRef
38.
Voon V et al (2007) Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 64(2):212–216PubMedCrossRef
39.
Gallagher DA et al (2007) Pathological gambling in Parkinson’s disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 22(12):1757–1763PubMedCrossRef
40.
Vitale C et al (2011) Comparative neuropsychological profile of pathological gambling, hypersexuality, and compulsive eating in Parkinson’s disease. Mov Disord 26(5):830–836PubMedCrossRef
41.
Grosset KA et al (2006) Problematic gambling on dopamine agonists: not such a rarity. Mov Disord 21(12):2206–2208PubMedCrossRef
42.
Antonini A et al (2011) Impulsivity and compulsivity in drug-naive patients with Parkinson’s disease. Mov Disord 26(3):464–468PubMedCrossRef
43.
Weintraub D et al (2013) Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology 80(2):176–180PubMedCentralPubMedCrossRef
44.
Driver-Dunckley ED et al (2007) Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome. Clin Neuropharmacol 30(5):249–255
45.
Holman AJ (2009) Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. J Gambl Stud 25(3):425–431PubMedCrossRef
46.
Falhammar H, Yarker JY (2009) Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med J Aust 190(2):97PubMed
47.
Weintraub D (2008) Dopamine and impulse control disorders in Parkinson’s disease. Ann Neurol 64(Suppl 2):S93–S100PubMedCentralPubMed
48.
Leroi I et al (2012) Apathy and impulse control disorders in Parkinson’s disease: a direct comparison. Parkinsonism Relat Disord 18(2):198–203PubMedCrossRef
49.
Santangelo G et al (2009) Cognitive dysfunctions and pathological gambling in patients with Parkinson’s disease. Mov Disord 24(6):899–905PubMedCrossRef
50.
Blum K et al (1995) Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics 5(3):121–141PubMedCrossRef
51.
Comings DE et al (1999) Studies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive behaviors: tourette syndrome, ADHD, pathological gambling, and substance abuse. Am J Med Genet 88(4):358–368PubMedCrossRef
52.
de Castro IP (1997) Genetic association study between pathological gambling and a functional DNA polymorphism at the D4 receptor gene. Pharmacogenetics 7(5):345–348CrossRef
53.
Lee JY et al (2012) Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson’s disease. Parkinsonism Relat Disord 18(1):76–78PubMedCrossRef
54.
Lundstrom K, Turpin MP (1996) Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 225(3):1068–1072PubMedCrossRef
55.
Brewer JA, Potenza MN (2008) The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol 75(1):63–75PubMedCentralPubMedCrossRef
56.
McFarland K, Lapish CC, Kalivas PW (2003) Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J Neurosci 23(8):3531–3537PubMed
57.
Vallelunga A et al (2012) Role of genetic polymorphisms of the dopaminergic system in Parkinson’s disease patients with impulse control disorders. Parkinsonism Relat Disord 18(4):397–399PubMedCrossRef
58.
Nuytemans K et al (2009) Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. Hum Mutat 30(7):1054–1061PubMedCrossRef
59.
60.
Steeves TD et al (2009) Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 132(Pt 5):1376–1385PubMedCentralPubMedCrossRef
61.
Guthrie M, Myers CE, Gluck MA (2009) A neurocomputational model of tonic and phasic dopamine in action selection: a comparison with cognitive deficits in Parkinson’s disease. Behav Brain Res 200(1):48–59PubMedCentralPubMedCrossRef
62.
Grace AA (2000) The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction 95(Suppl 2):S119–S128PubMedCrossRef
63.
Cilia R et al (2008) Functional abnormalities underlying pathological gambling in Parkinson disease. Arch Neurol 65(12):1604–1611PubMedCrossRef
64.
Joutsa J et al (2012) Increased medial orbitofrontal [18F] fluorodopa uptake in Parkinsonian impulse control disorders. Mov Disord 27(6):778–782PubMedCrossRef
65.
66.
Martin-Soelch C et al (2003) Neural activity related to the processing of increasing monetary reward in smokers and nonsmokers. Eur J Neurosci 18(3):680–688PubMedCrossRef
67.
Evans AH et al (2006) Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 59(5):852–858PubMedCrossRef
68.
Reuter J et al (2005) Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 8(2):147–148PubMedCrossRef
69.
Driver-Dunckley E, Samanta J, Stacy M (2003) Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease. Neurology 61(3):422–423PubMedCrossRef
70.
Dodd ML et al (2005) Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 62(9):1377–1381PubMedCrossRef
71.
Cools R et al (2001) Enhanced or impaired cognitive function in Parkinson’s disease as a function of dopaminergic medication and task demands. Cereb Cortex 11(12):1136–1143PubMedCrossRef
72.
Djamshidian A et al (2012) Decision making, impulsivity, and addictions: do Parkinson’s disease patients jump to conclusions? Mov Disord 27(9):1137–1145PubMedCentralPubMedCrossRef
73.
74.
Rabinak CA, Nirenberg MJ (2010) Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 67(1):58–63PubMedCrossRef
75.
Pondal M et al (2013) Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry 84(2):130–135PubMedCrossRef
76.
Cunnington AL, White L, Hood K (2012) Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson’s disease. Parkinsonism Relat Disord 18(9):1051–1052PubMedCrossRef
77.
Papay K et al (2011) Patient versus informant reporting of ICD symptoms in Parkinson’s disease using the QUIP: validity and variability. Parkinsonism Relat Disord 17(3):153–155PubMedCentralPubMedCrossRef
78.
79.
Visser M et al (2007) Assessment of psychiatric complications in Parkinson’s disease: the SCOPA-PC. Mov Disord 22(15):2221–2228PubMedCrossRef
80.
Christenson GA et al (1994) Compulsive buying: descriptive characteristics and psychiatric comorbidity. J Clin Psychiatry 55(1):5–11PubMed
81.
Lesieur HR, Blume SB (1987) The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers. Am J Psychiatry 144(9):1184–1188PubMedCrossRef
82.
83.
84.
Sohtaoglu M et al (2010) Long term follow-up of Parkinson’s disease patients with impulse control disorders. Parkinsonism Relat Disord 16(5):334–337PubMedCrossRef
85.
Ardouin C et al (2006) Pathological gambling in Parkinson’s disease improves on chronic subthalamic nucleus stimulation. Mov Disord 21(11):1941–1946PubMedCrossRef
86.
Bandini F et al (2007) Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson’s disease. Parkinsonism Relat Disord 13(6):369–371PubMedCrossRef
87.
Eusebio A et al (2013) Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson’s disease. J Neurol Neurosurg Psychiatry 84(8):868–874PubMedCrossRef
88.
Smeding HM et al (2007) Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry 78(5):517–519PubMedCentralPubMedCrossRef
89.
Moum SJ et al (2012) Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One 7(1):e29768PubMedCentralPubMedCrossRef
90.
Kim YE et al (2013) Impulse control and related behaviors after bilateral subthalamic stimulation in patients with Parkinson’s disease. J Clin Neurosci 20(7):964–969PubMedCrossRef
91.
Lhommee E et al (2012) Subthalamic stimulation in Parkinson’s disease: restoring the balance of motivated behaviours. Brain 135(Pt 5):1463–1477PubMedCrossRef
92.
Krack P et al (1998) Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson’s disease. Brain 121(Pt 3):451–457PubMedCrossRef
93.
Rogers RD et al (2011) Deep brain stimulation of the subthalamic nucleus transiently enhances loss-chasing behaviour in patients with Parkinson’s disease. Exp Neurol 231(1):181–189PubMedCrossRef
94.
Thomas A et al (2010) Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 68(3):400–404PubMedCrossRef
95.
Lee JY, Kim HJ, Jeon BS (2011) Is pathological gambling in Parkinson’s disease reduced by amantadine? Ann Neurol 69(1):213–214 (author reply 214–215)PubMedCrossRef
96.
Walsh RA, Lang AE (2012) Multiple impulse control disorders developing in Parkinson’s disease after initiation of amantadine. Mov Disord 27(2):326PubMedCrossRef
97.
Weintraub D et al (2010) Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 68(6):963–968PubMedCrossRef
98.
Grant JE, Potenza MN (2004) Impulse control disorders: clinical characteristics and pharmacological management. Ann Clin Psychiatry 16(1):27–34PubMedCrossRef
99.
Fong T et al (2008) A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav 89(3):298–303PubMedCrossRef
100.
Seedat S et al (2000) Pathological gambling behaviour: emergence secondary to treatment of Parkinson’s disease with dopaminergic agents. Depress Anxiety 11(4):185–186PubMedCrossRef
101.
Bostwick JM et al (2009) Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clin Proc 84(4):310–316PubMedCentralPubMedCrossRef
102.
Rotondo A et al (2010) Clozapine for medication-related pathological gambling in Parkinson disease. Mov Disord 25(12):1994–1995PubMedCrossRef
103.
Sevincok L, Akoglu A, Akyol A (2007) Quetiapine in a case with Parkinson disease and pathological gambling. J Clin Psychopharmacol 27(1):107–108PubMedCrossRef
104.
Hicks CW et al (2011) Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson’s disease. Parkinsonism Relat Disord 17(5):379–381PubMedCrossRef
105.
Bermejo PE (2008) Topiramate in managing impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord 14(5):448–449PubMedCrossRef
106.
Bermejo PE, Ruiz-Huete C, Anciones B (2010) Zonisamide in managing impulse control disorders in Parkinson’s disease. J Neurol 257(10):1682–1685PubMedCrossRef
107.
Gerschlager W, Bloem BR (2009) Managing pathological gambling in Parkinson’s disease with enteral levodopa/carbidopa infusions. Mov Disord 24(12):1858–1860PubMedCrossRef
108.
Grant JE et al (2006) Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 163(2):303–312PubMedCrossRef
109.
Kim SW et al (2001) Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 49(11):914–921PubMedCrossRef
110.
Schreiber L, Odlaug BL, Grant JE (2011) Impulse control disorders: updated review of clinical characteristics and pharmacological management. Front Psychiatry 2:1PubMedCentralPubMedCrossRef
111.
Grant JE, Kim SW, Odlaug BL (2007) N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry 62(6):652–657PubMedCrossRef
112.
Leroi I et al (2012) Carer burden in apathy and impulse control disorders in Parkinson's disease. Int J Geriatr Psychiatry 27(2):160–166. doi:10.​1002/​gps.​2704
113.
A’Campo LE et al (2012) Treatment effect modifiers for the patient education programme for Parkinson’s disease. Int J Clin Pract 66(1):77–83PubMedCrossRef
114.
Roland KP, Jenkins ME, Johnson AM (2010) An exploration of the burden experienced by spousal caregivers of individuals with Parkinson’s disease. Mov Disord 25(2):189–193PubMedCrossRef
115.
Brodaty H, Hadzi-Pavlovic D (1990) Psychosocial effects on carers of living with persons with dementia. Aust N Z J Psychiatry 24(3):351–361PubMedCrossRef
116.
Schulz R et al (1995) Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates, and causes. Gerontologist 35(6):771–791PubMedCrossRef
117.
Clare L et al (2002) Depression and anxiety in memory clinic attenders and their carers: implications for evaluating the effectiveness of cognitive rehabilitation interventions. Int J Geriatr Psychiatry 17(10):962–967PubMedCrossRef
118.
Cooper C, Balamurali TB, Livingston G (2007) A systematic review of the prevalence and covariates of anxiety in caregivers of people with dementia. Int Psychogeriatr 19(2):175–195PubMedCrossRef
119.
Cooper C et al (2007) A systematic review of intervention studies about anxiety in caregivers of people with dementia. Int J Geriatr Psychiatry 22(3):181–188PubMedCrossRef
120.
Cuijpers P (2005) Depressive disorders in caregivers of dementia patients: a systematic review. Aging Ment Health 9(4):325–330PubMedCrossRef
121.
Fiore J, Becker J, Coppel DB (1983) Social network interactions: a buffer or a stress. Am J Community Psychol 11(4):423–439PubMedCrossRef
122.
Dura JR, Stukenberg KW, Kiecolt-Glaser JK (1990) Chronic stress and depressive disorders in older adults. J Abnorm Psychol 99(3):284–290PubMedCrossRef
123.
Carter JH et al (2008) Do motor and nonmotor symptoms in PD patients predict caregiver strain and depression? Mov Disord 23(9):1211–1216PubMedCrossRef
124.
O’Reilly F et al (1996) The effects of caring for a spouse with Parkinson’s disease on social, psychological and physical well-being. Br J Gen Pract 46(410):507–512PubMedCentralPubMed
125.
Baumgarten M et al (1992) The psychological and physical health of family members caring for an elderly person with dementia. J Clin Epidemiol 45(1):61–70PubMedCrossRef
126.
Haley WE et al (2004) Well-being, appraisal, and coping in African-American and Caucasian dementia caregivers: findings from the REACH study. Aging Ment Health 8(4):316–329PubMedCrossRef
127.
Vedhara K et al (1999) Chronic stress in elderly carers of dementia patients and antibody response to influenza vaccination. Lancet 353(9153):627–631PubMedCrossRef
128.
Lee S et al (2003) Caregiving and risk of coronary heart disease in US women: a prospective study. Am J Prev Med 24(2):113–119PubMedCrossRef
129.
Kiecolt-Glaser JK et al (1991) Spousal caregivers of dementia victims: longitudinal changes in immunity and health. Psychosom Med 53(4):345–362PubMedCrossRef
130.
Pinquart M, Sorensen S (2003) Differences between caregivers and non caregivers in psychological health and physical health: a meta-analysis. Psychol Aging 18(2):250–267PubMedCrossRef
131.
Bauer ME et al (2000) Chronic stress in caregivers of dementia patients is associated with reduced lymphocyte sensitivity to glucocorticoids. J Neuroimmunol 103(1):84–92PubMedCrossRef
132.
133.
Vitaliano PP, Zhang J, Scanlan JM (2003) Is caregiving hazardous to one’s physical health? A meta-analysis. Psychol Bull 129(6):946–972PubMedCrossRef
134.
Wimo A, Jonsson L, Winblad B (2006) An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 21(3):175–181PubMedCrossRef
135.
Cassie KM, Sanders S (2008) Familial caregivers of older adults. J Gerontol Soc Work 50(Suppl 1):293–320PubMedCrossRef
136.
137.
138.
National Opinion Research Center at the University of Chicago (NORC) (1999) Gambling Impact and Behavior Study: report to the National Gambling Impact Study Commission. Government Printing Office, Washington DC
139.
Shaw MC et al (2007) The effect of pathological gambling on families, marriages, and children. CNS Spectr 12(8):615–622PubMedCrossRef
140.
Ciarrocchi J, Reinert D (1993) Family environment and length of recovery for married male members of Gamblers Anonymous and female members of GamAnon. J Gambl Stud 9(4):341–352CrossRef
141.
Muelleman RL et al (2002) Problem gambling in the partner of the emergency department patient as a risk factor for intimate partner violence. J Emerg Med 23(3):307–312PubMedCrossRef
142.
Jacobs DF et al (1989) Children of problem gamblers. J Gambl Behav 5(4):261–268CrossRef
143.
Weintraub D, Potenza MN (2006) Impulse control disorders in Parkinson’s disease. Curr Neurol Neurosci Rep 6(4):302–306PubMedCrossRef
Metadaten
Titel
Impulse control disorders in Parkinson’s disease: an overview from neurobiology to treatment
verfasst von
Emke Maréchal
Benjamin Denoiseux
Ellen Thys
David Crosiers
Barbara Pickut
Patrick Cras
Publikationsdatum
01.01.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 1/2015
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-014-7361-4

Weitere Artikel der Ausgabe 1/2015

Journal of Neurology 1/2015 Zur Ausgabe

Letter to the Editors

Does the vestibular system determine the lateralization of brain functions?

Original Communication

Boucher–Neuhäuser syndrome: cerebellar degeneration, chorioretinal dystrophy and hypogonadotropic hypogonadism: two novel cases and a review of 40 cases from the literature

Erratum

Erratum to: Autonomic symptoms in idiopathic REM behavior disorder: a multicentre case–control study

Letter to the Editors

Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome-like exacerbation after natalizumab withdrawal: a case report

Original Communication

Frontostriatal dysexecutive syndrome: a core cognitive feature of myotonic dystrophy type 2

Original Communication

Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise